Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab [1]

Rheumatology

Volumn 43, Issue 4, 2004, Pages 522-523

  Molloy, E ^a   Ramakrishnan, S ^a   Murphy, E ^a   Barry, M ^a  

^a Royal College of Surgeons in Ireland   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDIASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HISTOPLASMOSIS; HUMAN; INFECTION RISK; LETTER; MORBIDITY; MORTALITY; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCREENING TEST;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FATAL OUTCOME; FEMALE; HUMANS; MALE;

EID: 1842844292     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh076     Document Type: Letter

References (6)

1. Kalden J. Expanding role of biologic agents in rheumatoid arthritis. J Rheumatol 2002;29:27-37.
2. Moots R, Taggart A, Walker D. Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology 2003;42: 614-6.
3. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
4. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48: 1853-7.
5. Tai TL, O'Rourke K, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002;41:951-2.
6. Ruderman JM, Markenson JA. Granulomatous infections and tumour necrosis factor antagonist therapies. Ann Rheum Dis 2003;62:172-3.